Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Molecular markers and targeted therapies for adrenocortical carcinoma

Yunze Xu1, Yicheng Qi, Yu Zhu

  • 1Department of Urology, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China; Department of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.

Clinical Endocrinology
|December 6, 2013
PubMed

Insights

Adrenocortical carcinoma (ACC) is a deadly cancer with limited treatments. This review explores genetic mutations and molecular pathways driving ACC, highlighting targeted therapy potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Adrenocortical carcinoma (ACC) presents a significant clinical challenge due to its poor prognosis and limited effective therapeutic strategies.
  • Current systemic treatments for advanced ACC yield disappointing outcomes, underscoring the need for novel therapeutic approaches.

Purpose of the Study:

  • To review the current understanding of molecular alterations in adrenocortical carcinogenesis.
  • To present the rationale for investigating targeted therapies in ACC.

Main Methods:

  • Literature review of recent advancements in adrenocortical carcinoma research.
  • Analysis of identified genetic mutations and molecular pathways in sporadic ACC.
  • Summary of preclinical and clinical investigations into targeted therapies.

Main Results:

  • Identification of key genetic mutations contributing to ACC development.
  • Elucidation of molecular mechanisms underlying ACC pathophysiology.
  • Initiation of clinical trials for tyrosine kinase inhibitors and anti-angiogenic agents.

Conclusions:

  • Molecular analysis has advanced the understanding of ACC development and identified prognostic markers.
  • Targeted therapies show promise for improving outcomes in adrenocortical carcinoma.

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

26.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K